 Pre-Exposure Prophylaxis
"Pre-Exposure Prophylaxis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of disease prevention (abbreviated PrEP) which involves the administration of drugs to at-risk persons who have not been exposed to the disease-causing agent.
| Descriptor ID |
D065129
|
| MeSH Number(s) |
N02.421.726.758.655 N06.850.780.680.655
|
| Concept/Terms |
Pre-Exposure Prophylaxis- Pre-Exposure Prophylaxis
- Pre Exposure Prophylaxis
- Pre-Exposure Prophylaxi
- Prophylaxi, Pre-Exposure
- Prophylaxis, Pre-Exposure
- Pre-Exposure Prophylaxis (PrEP)
- Pre Exposure Prophylaxis (PrEP)
- Pre-Exposure Prophylaxi (PrEP)
- Prophylaxi, Pre-Exposure (PrEP)
- Prophylaxis, Pre-Exposure (PrEP)
|
Below are MeSH descriptors whose meaning is more general than "Pre-Exposure Prophylaxis".
Below are MeSH descriptors whose meaning is more specific than "Pre-Exposure Prophylaxis".
This graph shows the total number of publications written about "Pre-Exposure Prophylaxis" by people in this website by year, and whether "Pre-Exposure Prophylaxis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 3 | 1 | 4 | | 2015 | 4 | 2 | 6 | | 2016 | 9 | 0 | 9 | | 2017 | 13 | 2 | 15 | | 2018 | 16 | 5 | 21 | | 2019 | 11 | 5 | 16 | | 2020 | 10 | 4 | 14 | | 2021 | 28 | 2 | 30 | | 2022 | 20 | 0 | 20 | | 2023 | 14 | 0 | 14 | | 2024 | 15 | 1 | 16 | | 2025 | 14 | 2 | 16 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pre-Exposure Prophylaxis" by people in Profiles.
-
Ustianowski A, Levin MJ, De Wit S, Launay O, Veekmans B, Rampling T, Sullivan JG, Vishnepolsky M, Wijewardane P, Fawadleh Y, Zhang H, Li M, Wickramarachchi D, Sharbaugh A, Beavon R, Thissen J, Hirao L, Dzutseva V, Seegobin S, Streicher K, Kiazand A, Esser MT, Chang LJ, Perez JL, Cohen TS. Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study. Clin Drug Investig. 2026 Feb; 46(2):207-219.
-
Miller SE, Dukes KA, Damato-MacPherson C, Psaros C, Scott NA, Taylor JL, Muroff J, Winter MR, Skiba LE, Lugo H, Cruz R, Ruiz-Mercado G, Crawford ND, Mayer KH, Assoumou SA. Pre-exposure prophylaxis (PrEP) and medications for opioid use disorder for persons who inject drugs: the CHORUS?+?randomized controlled trial study protocol. Addict Sci Clin Pract. 2025 Dec 25; 21(1):17.
-
Abuogi LL, Imran R, Limas A, Moor J, Leonard K, Pierce K, De La Garza AJ, Gallegos S, Duenas J, Littrell Z, Vyas P, Richards M, Straub D, McFarland EJ. Pilot outcomes of a telehealth model for youth PrEP (TelePrEP) among youth at risk for HIV in Colorado. HIV Res Clin Pract. 2025 Dec 31; 26(1):2588009.
-
Cianelli R, De Santis JP, Iriarte E, De Oliveira GC, Williams R, Placide Reaves R, Castro JG, Hodge S, Thomas SO, Edwards C, Baeza Robba MJ, Villegas N, Montano NP. SEPA+PrEP-BW intervention: A feasible and acceptable HIV prevention intervention for Black women. PLoS One. 2025; 20(11):e0336435.
-
Beyrer C, Remien RH, Eshleman SH, Gamble TR, De Dieu Tapsoba J, Labbett RL, Sullivan PA, Laeyendecker O, Anderson PL, Agravat D, Hughes JP, Driffin DD, Hutchinson CS, Hucks-Ortiz C, Adair M, Curry M, Jones SB, Haddock IL, Boyd D, Burwen DR, Johnson AS, Nelson LE. Investigating the HIV epidemic among Black gay and bisexual men in the Southern United States: Results of the HPTN 096 pilot cross-sectional assessment. PLoS One. 2025; 20(10):e0334031.
-
Engel N, Sykes C, Schauer AP, Kashuba ADM, Anderson PL, Bushman LR, Cottrell ML. Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application. J Antimicrob Chemother. 2025 Oct 03; 80(10):2727-2731.
-
Hampanda K, Bolt M, Nayame L, Sehrt M, Thorne J, Hamoonga TE, Harrison MS, Pintye J, Amstutz A, Abuogi LL, Mweemba O. HIV Risk and Intention to Use HIV Pre-exposure Prophylaxis Among Sexually Active Female University Students in Zambia: A Cross-Sectional Survey to Understand Influential Factors. AIDS Patient Care STDS. 2025 Oct; 39(10):418-426.
-
Anderson PL, Coppinger C, Cottrell ML, Marzinke MA. Recommendations for Interpreting Intraerythrocytic Tenofovir Diphosphate and Emtricitabine Triphosphate for HIV-1 Preexposure Prophylaxis Adherence Assessment. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):162-169.
-
Hamoonga TE, Hampanda K, Sehrt M, Nayame L, Mumbula I, Thorne J, Mulawa MJ, Mweemba O. End-user preferences for biomedical HIV prevention products and service delivery models: a mixed methods study with female university students in Zambia. AIDS Care. 2025 Nov; 37(11):1857-1867.
-
Mugwanya KK, Saina M, Mugo NR, MaWhinney S, Morrow M, Schaafsma TT, Donnell D, Glidden DV, Ngure K, Brown CE, Rechkina EA, Chohan BH, Wu L, Hill E, Koome E, Akelo N, Mbaire S, Morrison SA, Kibatha M, Njeru I, Muriithi M, Coppinger C, Bushman L, Baeten JM, Anderson PL. Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study. PLoS Med. 2025 Sep; 22(9):e1004732.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|